(Q33323936)

25 July 2017

title

The 5-HT3 receptor antagonist ondansetron re-establishes control in refractory emesis induced by non-cisplatin chemotherapy (English)

1 reference

25 July 2017

1 reference

1

Seynaeve C

1 reference

25 July 2017

de Mulder PH

2

1 reference

25 July 2017

Lane-Allman E

series ordinal

3

1 reference

25 July 2017

van Liessum PA

series ordinal

4

1 reference

25 July 2017

Verweij J

series ordinal

5

1 reference

25 July 2017

publication date

1 July 1991

1 reference

25 July 2017

1 reference

25 July 2017

volume

3

1 reference

25 July 2017

issue

4

1 reference

25 July 2017

page(s)

199-203

1 reference

Identification of 5-HT3 recognition sites in human brain tissue using [3H]zacopride

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980739-3

7 January 2021

Methylprednisolone for the control of CMF-induced emesis

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980739-3

7 January 2021

Efficacy of Ondansetron (Gr 38032F) and the Role of Serotonin in Cisplatin-Induced Nausea and Vomiting

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980739-3

7 January 2021

High-dose oral and intravenous metoclopramide in doxorubicin/cyclophosphamide-induced emesis. A randomized double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980739-3

7 January 2021

Peripheral 5-hydroxytryptamine receptors and their classification

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980739-3

7 January 2021

Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980739-3

7 January 2021

Extrapyramidal reactions with high-dose metoclopramide

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980739-3

7 January 2021

Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980739-3

7 January 2021

Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomised trial of antiemetics.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980739-3

7 January 2021

Antiemetic properties of the 5HT3-receptor antagonist, GR38032F

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980739-3

7 January 2021

Anticipatory nausea and vomiting: does it remain a significant clinical problem?

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980739-3

7 January 2021

Intravenous metoclopramide: prevention of chemotherapy-induced nausea and vomiting. A preliminary evaluation.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980739-3

7 January 2021

10.1016/S0936-6555(05)80739-3

Identifiers

DOI

1 reference

25 July 2017

1 reference